Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24513247 | 0.87 | KDM4E (0.38) | PIK3CDTSHRL3MBTL1KDM4EGLA | |
| SCHEMBL12021824 | 0.85 | MEN1 (0.39) | KMT2ATSHRL3MBTL1KDM4EGLA | |
| SCHEMBL20938774 | 0.84 | HRH3 (0.43) | KMT2A | |
| SCHEMBL20886095 | 0.82 | USP2 (0.42) | PIK3CDKMT2ATSHRKDM4E | |
| SCHEMBL19228630 | 0.81 | USP2 (0.41) | LMNATSHRKDM4E | |
| SCHEMBL24607411 | 0.80 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL21258506 | 0.80 | TSHR (0.33) | TSHRL3MBTL1KDM4EGLA | |
| SCHEMBL17108662 | 0.77 | PIK3CD (0.48) | PIK3CDL3MBTL1 | |
| SCHEMBL20344871 | 0.77 | GPR88 (0.40) | TSHRL3MBTL1KDM4EGLA | |
| SCHEMBL22550830 | 0.77 | KDM4E (0.40) | PIK3CDTSHRL3MBTL1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3683207-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Cadent Therapeutics, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |